3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Cyclophosphamide
176
Rituximab
164
fludarabine phosphate
97
Peripheral Blood Stem Cell Transplantation
95
Filgrastim
73
Etoposide
67
Radiotherapy
63
Mycophenolic Acid
62
Whole-Body Irradiation
58
Tacrolimus
49
Melphalan
49
Cyclosporine
49
Busulfan
47
Lenalidomide
45
Antilymphocyte Serum
39
Vincristine
37
Prednisone
37
Cytarabine
37
fludarabine
35
Methotrexate
33
Carmustine
32
obinutuzumab
31
Doxorubicin
30
Bendamustine Hydrochloride
30
Methylprednisolone
27
ibritumomab tiuxetan
25
Cord Blood Stem Cell Transplantation
25
sargramostim
24
Bortezomib
24
Granulocyte Colony-Stimulating Factor
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, Follicular
×
High-Intensity Interval Training
×
Clear all
NCT04902092
2023-10-23
BEAT
Monash University
Phase NA
Completed
65 enrolled